New Breakthrough in Repurposing Drugs for Rare Diseases

Ashlins Pharmaceuticals, a U.S.-based startup specializing in rare diseases, has entered into an agreement with Lee's Pharmaceutical of Hong Kong to acquire the ex-China rights to Interferon alpha-2b for up to $31 million. This deal addresses the supply gap in treatments for rare diseases that emerged when Merck & Co. discontinued production of its existing treatment, Intron A, for commercial reasons in 2022. Ashlins aims to leverage this asset to develop a formally FDA-approved treatment for rare and difficult-to-treat diseases, moving away from the conventional approach of starting drug development from scratch. This represents a strategic effort to significantly improve the success rate of drug development by repurposing a substance with proven safety and efficacy.

Synergy Between Chinese Manufacturing Capabilities and Global Licensing

Through this partnership, Ashlins will secure a supply chain of high-quality active pharmaceutical ingredients (APIs) produced in China. By utilizing China's cost-effective manufacturing infrastructure, the company aims to significantly reduce clinical trial costs and accelerate development. Given that the agreement was concluded through Ashlins' ophthalmic subsidiary, Ashlins Ocular Pharmaceuticals, rare inflammatory diseases of the eye that require the immune-modulating function of Interferon alpha-2b are expected to be key targets. This strategy involves rapidly capturing niche markets overlooked by global pharmaceutical companies by combining them with superior production capabilities from other regions.

Rapid Clinical Entry Through Pre-IND Meeting

The company is scheduled to hold a pre-IND (Investigational New Drug) meeting with the FDA in early August 2026, suggesting a rapid entry into clinical trials. As it is an ingredient widely used as Intron A, it has the advantage of significantly shortening the pre-clinical stage compared to new substances. Industry experts believe that if regulatory authorities recognize the existing safety data, there is a high possibility of skipping Phase 1 clinical trials and proceeding directly to later-stage trials. This significantly reduces risks in terms of time and cost, and provides a favorable position for attracting investment.

Peter Thiel's Support and $50 Million Funding Round

Jennifer Lin, founder and CEO of Ashlins, is a recipient of the Thiel Fellowship from billionaire Peter Thiel and has received initial investment from Mythos Ventures, a Silicon Valley venture capital firm, attracting market attention. The company plans to complete a funding round of approximately $50 million in October, and this funding will be a key driver for obtaining FDA approval and building additional pipelines. With its ties to the Thiel network and abundant human resources, Ashlins is charting a differentiated growth path, relatively easily securing capital amidst the financial difficulties faced by typical biotech companies.

Competition with Existing Standard Treatments and Market Outlook

Intron A, which previously recorded annual sales of over $1 billion, saw its sales decline to less than $10 million due to the development of treatments for hepatitis C, leading to its discontinuation. Ashlins aims to fill this void by targeting the ophthalmology field and other areas, offering an alternative to existing treatments such as corticosteroids and immunosuppressants, which have significant side effects. In particular, it can provide a strong alternative for patients with rare ophthalmic diseases such as Behcet's disease, who are at risk of blindness due to a lack of standard treatments. In the future, clinical data and FDA approval will be key indicators that will determine the company's value and commercial success.

Why This Matters

The strategy of repurposing Interferon alpha-2b (Intron A), a proven drug that previously generated over $1 billion in annual sales, for rare inflammatory ophthalmic diseases is considered a business model that maximizes regulatory and development success rates in drug development. In the short term, the results of the FDA pre-IND meeting scheduled for early August 2026 and the success of the $50 million Series A funding round targeted for completion in October will be key milestones in demonstrating Ashlins' initial corporate value. In the medium to long term, it has the potential to establish itself as a clear alternative standard of care (SoC) in the rare inflammatory ophthalmic disease market, which is currently dominated by treatments such as corticosteroids and anti-TNF biologics with significant side effects. The milestone payments of up to $31 million included in the ex-China agreement with Lee's Pharmaceutical provide an opportunity to secure a competitive advantage in the exclusive supply of APIs and accelerate global market expansion.